​

Janux Therapeutics (JANX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

JANX Stock Forecast

Janux Therapeutics (JANX) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $28.25, with a high of $55.00 and a low of $14.00. This represents a 46.15% increase from the last price of $19.33.

$10 $20 $30 $40 $50 $60 High: $55 Avg: $28.25 Low: $14 Last Closed Price: $19.33

JANX Stock Rating

Janux Therapeutics stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (75.00%), 3 Hold (18.75%), 1 Sell (6.25%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 1 3 12 Strong Sell Sell Hold Buy Strong Buy

JANX Price Target Upside V Benchmarks

TypeNameUpside
StockJanux Therapeutics46.15%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1414
Avg Price Target$23.00$34.75$33.71
Last Closing Price$19.33$19.33$19.33
Upside/Downside18.99%79.77%74.39%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 262141-118
Aug, 262132-118
Jul, 262132-118
Jun, 262132-118
May, 262132-118
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 24, 2026Wolfe Research$23.00$17.3932.26%18.99%
Aug 07, 2026Stifel Nicolaus$35.00$16.00118.75%81.07%
Aug 07, 2026Guggenheim$55.00$16.10241.61%184.53%
Jun 25, 2026Truist Financial$26.00$14.6477.60%34.51%
May 11, 2026Evercore ISI$22.00$14.4052.78%13.81%
May 08, 2026Wedbush$36.00$14.33151.22%86.24%
Apr 20, 2026Etzer DaroutBarclays$14.00$15.82-11.50%-27.57%
Apr 15, 2026UBS$15.00$15.24-1.57%-22.40%
Jan 16, 2026Kelsey GoodwinPiper Sandler$30.00$13.72118.66%55.20%
Dec 17, 2025Barclays$29.00$14.6597.95%50.03%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 24, 2026Wolfe ResearchOutperformupgrade
Apr 20, 2026BarclaysOverweightUnderweightdowngrade
Apr 15, 2026UBSBuyNeutraldowngrade
Jan 16, 2026Piper SandlerOverweightOverweighthold
Dec 02, 2025UBSBuyBuyhold
Dec 02, 2025Cantor FitzgeraldOverweightOverweighthold
Sep 16, 2025BarclaysOverweightinitialise
Sep 03, 2025GuggenheimBuyinitialise
Aug 18, 2025Piper SandlerOverweightinitialise
Jul 11, 2025Raymond JamesOutperforminitialise

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.79$-1.52$-1.32$-1.28$-1.83---
Avg Forecast$-1.25$-1.65$-1.52$-1.42$-1.93$-2.55$-3.24$-2.59
High Forecast$-1.10$-1.55$-1.37$-1.32$-1.19$-1.13$-1.19$-2.59
Low Forecast$-1.54$-2.02$-1.70$-1.66$-3.06$-6.06$-5.89$-2.59
Surprise %-36.80%-7.88%-13.16%-9.86%-5.18%---

Revenue Forecast

$0 $20M $40M $60M $80M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.64M$8.61M$8.08M$10.59M$10.00M---
Avg Forecast$2.45M$6.58M$6.37M$12.30M$5.32M$12.84M$10.29M$98.70M
High Forecast$2.89M$7.72M$6.78M$12.65M$5.54M$12.84M$10.29M$98.70M
Low Forecast$2.23M$6.29M$5.71M$12.18M$5.10M$12.84M$10.29M$98.70M
Surprise %48.61%30.98%26.96%-13.90%88.08%---

Net Income Forecast

$-300M $-240M $-180M $-120M $-60M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-32.67M$-63.06M$-58.29M$-68.99M$-157.67M---
Avg Forecast$-54.91M$-72.41M$-67.69M$-60.54M$-116.23M$-162.08M$-218.30M$-113.90M
High Forecast$-48.63M$-68.27M$-60.42M$-57.94M$-52.39M$-49.62M$-52.54M$-113.90M
Low Forecast$-67.96M$-88.78M$-74.97M$-72.88M$-134.77M$-266.81M$-259.22M$-113.90M
Surprise %-40.50%-12.91%-13.89%13.97%35.65%---

JANX Forecast FAQ

Is Janux Therapeutics stock a buy?

Janux Therapeutics stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Janux Therapeutics is a favorable investment for most analysts.

What is Janux Therapeutics's price target?

Janux Therapeutics's price target, set by 16 Wall Street analysts, averages $28.25 over the next 12 months. The price target range spans from $14 at the low end to $55 at the high end, suggesting a potential 46.15% change from the previous closing price of $19.33.

How does Janux Therapeutics stock forecast compare to its benchmarks?

Janux Therapeutics's stock forecast shows a 46.15% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Janux Therapeutics over the past three months?

  • September 2026: 11.11% Strong Buy, 77.78% Buy, 5.56% Hold, 0% Sell, 5.56% Strong Sell.
  • August 2026: 11.11% Strong Buy, 72.22% Buy, 11.11% Hold, 0% Sell, 5.56% Strong Sell.
  • July 2026: 11.11% Strong Buy, 72.22% Buy, 11.11% Hold, 0% Sell, 5.56% Strong Sell.

What is Janux Therapeutics’s EPS forecast?

Janux Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.55, marking a 39.34% increase from the reported $-1.83 in 2025. Estimates for the following years are $-3.24 in 2027, and $-2.59 in 2028.

What is Janux Therapeutics’s revenue forecast?

Janux Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $12.84M, reflecting a 28.40% increase from the reported $10M in 2025. The forecast for 2027 is $10.29M, and $98.7M for 2028.

What is Janux Therapeutics’s net income forecast?

Janux Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-162M, representing an 2.80% increase from the reported $-158M in 2025. Projections indicate $-218M in 2027, and $-114M in 2028.